BR9808313A - Métodos para determinar a predisposição de um paciente à doença arterial coronariana e kit para previsão de doença arterial coronariana - Google Patents

Métodos para determinar a predisposição de um paciente à doença arterial coronariana e kit para previsão de doença arterial coronariana

Info

Publication number
BR9808313A
BR9808313A BR9808313-9A BR9808313A BR9808313A BR 9808313 A BR9808313 A BR 9808313A BR 9808313 A BR9808313 A BR 9808313A BR 9808313 A BR9808313 A BR 9808313A
Authority
BR
Brazil
Prior art keywords
coronary artery
artery disease
methods
patient
determining
Prior art date
Application number
BR9808313-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Sheila E Francis
David C Crossman
Gordon W Duff
Original Assignee
Medical Science Sys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Science Sys Inc filed Critical Medical Science Sys Inc
Publication of BR9808313A publication Critical patent/BR9808313A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
BR9808313-9A 1997-03-10 1998-03-09 Métodos para determinar a predisposição de um paciente à doença arterial coronariana e kit para previsão de doença arterial coronariana BR9808313A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/813,456 US6210877B1 (en) 1997-03-10 1997-03-10 Prediction of coronary artery disease
PCT/US1998/004725 WO1998040517A1 (en) 1997-03-10 1998-03-09 Prediction of coronary artery disease

Publications (1)

Publication Number Publication Date
BR9808313A true BR9808313A (pt) 2000-05-16

Family

ID=25212420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808313-9A BR9808313A (pt) 1997-03-10 1998-03-09 Métodos para determinar a predisposição de um paciente à doença arterial coronariana e kit para previsão de doença arterial coronariana

Country Status (22)

Country Link
US (1) US6210877B1 (OSRAM)
EP (1) EP0983381B1 (OSRAM)
JP (2) JP4250765B2 (OSRAM)
CN (1) CN100523214C (OSRAM)
AR (1) AR011943A1 (OSRAM)
AT (1) ATE370246T1 (OSRAM)
AU (1) AU738875B2 (OSRAM)
BR (1) BR9808313A (OSRAM)
CA (1) CA2282746C (OSRAM)
DE (2) DE69838250T2 (OSRAM)
DK (1) DK0983381T3 (OSRAM)
EA (1) EA199900813A1 (OSRAM)
ES (1) ES2156843T3 (OSRAM)
GR (1) GR20010300016T1 (OSRAM)
IL (1) IL131745A0 (OSRAM)
MX (1) MXPA99008223A (OSRAM)
NO (1) NO994365L (OSRAM)
NZ (1) NZ337642A (OSRAM)
PL (1) PL335603A1 (OSRAM)
PT (1) PT983381E (OSRAM)
WO (1) WO1998040517A1 (OSRAM)
ZA (1) ZA981937B (OSRAM)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720141B1 (en) 1999-11-01 2004-04-13 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US20050282198A1 (en) * 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
GB9723835D0 (en) * 1997-11-13 1998-01-07 Nicklin Martin Interleukin knockout
US6437216B1 (en) 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US20050032077A1 (en) * 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
AU769949B2 (en) * 1998-04-21 2004-02-12 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
US6733967B1 (en) 1998-04-21 2004-05-11 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
US6251598B1 (en) 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
JP2003500005A (ja) * 1999-02-10 2003-01-07 インターリューキン ジェネティックス インコーポレイテッド ＩＬ−１β遺伝子の突然変異に基づく治療および診断
JP2003500069A (ja) * 1999-05-24 2003-01-07 インタールーキン ジェネティックス インク 再狭窄の診断及び治療薬
IL147182A0 (en) * 1999-06-30 2002-08-14 Interleukin Genetics Inc Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplorype
EP1409737A4 (en) * 2001-06-15 2005-10-12 Interleukin Genetics Inc METHODS OF DETECTING AND TREATING EARLY APPEARANCE OF CONDITIONS RELATED TO AGING
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
CN1753903B (zh) 2001-11-19 2010-05-12 白介素遗传公司 影响转录和对炎性和传染性疾病的敏感性的白细胞介素-1基因座的功能多态性
EP1327639A1 (en) * 2002-01-15 2003-07-16 Bayer Ag Prediction of cardiovascular disease by genetic polymorphisms in cardiovascular associated genes
KR100924468B1 (ko) * 2002-01-25 2009-11-03 인터레우킨 제네틱스, 인코포레이티드 Ｉｌ-1 유전자 집단 및 관련된 염증성 다형성과 일배체형
US20070264645A1 (en) * 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
WO2004029618A2 (en) * 2002-09-30 2004-04-08 Novartis Ag Methods to predict cholesterol elevations during immunosuppressant therapy
US20050053956A1 (en) * 2002-11-13 2005-03-10 Dietz Harry C. Detection of a predisposition for the development of coronary artery disease
WO2004069867A2 (en) * 2003-02-03 2004-08-19 Bayer Healthcare Ag Genetic polymorphisms as predictive diagnostics for adverse drug reactions (adr) and drug efficacy
US7625699B2 (en) * 2003-03-10 2009-12-01 Celera Corporation Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof
EP1753875A2 (en) * 2004-05-07 2007-02-21 Applera Corporation Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8105775B2 (en) * 2005-10-25 2012-01-31 Interleukin Genetics, Inc. IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
RU2310862C1 (ru) * 2006-05-02 2007-11-20 Государственное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ выявления риска развития ишемической болезни сердца
US7935498B2 (en) * 2006-07-07 2011-05-03 Siemens Healthcare Diagnostics Inc. Methods for identifying patients with increased risk of an adverse cardiovascular event
ES2431671T3 (es) * 2006-11-15 2013-11-27 Interleukin Genetics, Inc. El complejo génico de IL-1 y resistencia a la insulina: polimorfismos asociados, haplotipos y métodos para usarlos
JP2011502510A (ja) * 2007-11-08 2011-01-27 インタールーキン ジェネティクス， インコーポレイテッド 老化に関係がある皮膚疾患の診断
US20100112570A1 (en) * 2008-10-22 2010-05-06 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
CN102747075B (zh) * 2012-06-07 2014-07-23 中国医学科学院阜外心血管病医院 与冠心病相关的6号染色体易感区域标签单核苷酸多态性位点及其组成的单体型与应用
JP2019503176A (ja) 2016-01-12 2019-02-07 インターロイキン ジェネティクス， インコーポレイテッド 処置に対する応答を予測するための方法
CN106202936A (zh) * 2016-07-13 2016-12-07 为朔医学数据科技（北京）有限公司 一种疾病风险预测方法及系统
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
CA3142662A1 (en) 2019-06-06 2020-12-10 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
CN110277137B (zh) * 2019-06-13 2022-03-18 南方医科大学顺德医院(佛山市顺德区第一人民医院) 一种用于检测冠心病的基因芯片信息处理系统及方法
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US5110920A (en) 1982-01-22 1992-05-05 Cetus Corporation HLA typing method and DNA probes used therein
US4623619A (en) 1982-03-03 1986-11-18 Nordisk Insulinlaboratorium Method for the determination of liability in human individuals to develop atherosclerosis
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5268267A (en) 1987-08-21 1993-12-07 The General Hospital Corporation Method for diagnosing small cell carcinoma
GB9301453D0 (en) * 1993-01-26 1993-03-17 Clonit Spa Nucleotide proves
US5658729A (en) 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5698399A (en) 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease

Also Published As

Publication number Publication date
JP2001514522A (ja) 2001-09-11
MXPA99008223A (es) 2003-07-21
NO994365D0 (no) 1999-09-09
DK0983381T3 (da) 2007-12-17
PL335603A1 (en) 2000-05-08
EP0983381A1 (en) 2000-03-08
DE69838250D1 (de) 2007-09-27
CN1255948A (zh) 2000-06-07
US6210877B1 (en) 2001-04-03
CA2282746C (en) 2009-02-24
JP2009077727A (ja) 2009-04-16
ES2156843T3 (es) 2008-04-16
DE69838250T2 (de) 2008-05-08
AU6457498A (en) 1998-09-29
DE983381T1 (de) 2000-11-09
GR20010300016T1 (en) 2001-04-30
CN100523214C (zh) 2009-08-05
PT983381E (pt) 2007-11-26
ATE370246T1 (de) 2007-09-15
EP0983381A4 (en) 2004-05-12
ES2156843T1 (es) 2001-08-01
AU738875B2 (en) 2001-09-27
NZ337642A (en) 2001-02-23
JP4250765B2 (ja) 2009-04-08
AR011943A1 (es) 2000-09-13
CA2282746A1 (en) 1998-09-17
WO1998040517A1 (en) 1998-09-17
ZA981937B (en) 1999-09-06
IL131745A0 (en) 2001-03-19
EA199900813A1 (ru) 2000-06-26
EP0983381B1 (en) 2007-08-15
NO994365L (no) 1999-11-09

Similar Documents

Publication Publication Date Title
CA2282746A1 (en) Prediction of coronary artery disease
Shen et al. Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan
Levy et al. Framingham Heart Study 100K Project: genome-wide associations for blood pressure and arterial stiffness
Shinn et al. Blood pressure and symptoms of depression and anxiety: a prospective study
Kapur et al. A prothrombin gene mutation is significantly associated with venous thrombosis
Salomon et al. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy
Aho et al. Epidemiology of rheumatoid arthritis in Finland
Esteghamat et al. CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation
Brattström et al. A common methylenetetrahydrofolate reductase gene mutation and longevity
EP1556405A4 (en) MUTATIONS IN NOD2 ARE ASSOCIATED TO PATIENTS WITH MORBUS CROHN WITH FIBROSTENOSIS
NO995803L (no) Forutsigelse av inflammatorisk sykdom assosiert med IL-1 genloki-polymorfisme
WO2002089657A3 (en) Diagnostic markers of acute coronary syndromes and methods of use thereof
Tan et al. FBN1 mutations largely contribute to sporadic non-syndromic aortic dissection
Sokol et al. Association of genetic variability in selected genes in patients with deep vein thrombosis and platelet hyperaggregability
Ortlepp et al. Additive effects of the chemokine receptor 2, vitamin D receptor, interleukin-6 polymorphisms and cardiovascular risk factors on the prevalence of myocardial infarction in patients below 65 years
Gupta et al. Role of ApoE gene polymorphism and nonconventional biochemical risk factors among very young individuals (aged less than 35 years) presenting with acute myocardial infarction
Dodson et al. The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion
Lin et al. A novel pathogenic HSPG2 mutation in Schwartz–Jampel syndrome
Bruscia et al. The sense of coherence in hospitalized cardiac and cancer patients
Canseco-Avila et al. Polymorphisms‐455G/A and‐148C/T and Fibrinogen Plasmatic Level as Risk Markers of Coronary Disease and Major Adverse Cardiovascular Events
WO2003020118A3 (en) Diagnosis and treatment of vascular disease
Serin et al. Biosensing strategies (approaches) for diagnosis and monitoring of multiple sclerosis
Lin et al. The prevalence of C677T mutation in the methylenetetrahydrofolate reductase gene and its association with venous thrombophilia in Taiwanese Chinese
Isasi et al. Inverse association of physical fitness with plasma fibrinogen level in children the Columbia University BioMarkers Study
Steffensen et al. Basement membrane proteins in various arterial beds from individuals with and without type 2 diabetes mellitus: a proteome study

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]